感染

订阅

MedSci主页 / 所有栏目 / 感染

JCI：联合化疗可有效治疗CVID患者继发性肺疾病

2012-09-07 丁香园 丁香园

联合化疗普通易变型免疫缺陷CVID肺病
关注

Wisconsin医科大学和Wisconsin研究所儿童医院的一个研究团队针对自身具有基础免疫缺陷（被称作普通易变型免疫缺陷，CVID）患者发生潜在致死性肺病定义了一个新的治疗方法，其研究结果发表在Clinical Immunology上。 普通易变型免疫缺陷（CVID）是最常见的原发性免疫缺陷病，需要定期药物治疗，特别是免疫球蛋白（抗体）的替代疗法。在免疫球蛋白治疗方案下，CVID患者因感染导

Wisconsin医科大学和Wisconsin研究所儿童医院的一个研究团队针对自身具有基础免疫缺陷（被称作普通易变型免疫缺陷，CVID）患者发生潜在致死性肺病定义了一个新的治疗方法，其研究结果发表在Clinical Immunology上。

普通易变型免疫缺陷（CVID）是最常见的原发性免疫缺陷病，需要定期药物治疗，特别是免疫球蛋白（抗体）的替代疗法。在免疫球蛋白治疗方案下，CVID患者因感染导致的死亡在减少，而因非感染性并发症导致的死亡在增加。CVID患者最常见的一种死因是肉芽肿淋巴细胞性间质性肺病（GLILD）。GLILD患者其自身白细胞会在肺内异常聚集，从而导致肺功能逐渐下降，最终转化为呼吸衰竭。研究人员在GLILD患者身上评估了利妥昔单抗和硫唑嘌呤（联合化疗）能否通过杀死在肺内异常聚集的白细胞来改善肺功能和/或影像学异常。
 
“用于GLILD最常见的药物是皮质类固醇激素，但从目前看来这类药物并不能清除疾病。因此，我们设计的治疗是靶向性地杀死特定类型的淋巴细胞——B细胞和T细胞，因为在肺活检过程中这两类细胞数目异常。我们确信如果杀死了肺内这些特定的淋巴细胞，肺功能和影像学异常情况都能得到改善，而结果也正如我们预想的那样。”Wisconsin医科大学哮喘、过敏及免疫学系主任兼Wisconsin研究所儿童医院过敏/临床免疫学医学顾问John M. Routes教授如是说。
 
链接;

Chase NM Verbsky JW Hintermeyer MK Waukau JK Tomita-Mitchell A Casper JT Singh S Shahir KS Tisol WB Nugent ML Rao RN Mackinnon AC Goodman LR Simpson PM Routes JM.Use of Combination Chemotherapy for Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Patients with Common Variable Immunodeficiency (CVID).J Clin Immunol 2012

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1989628, encodeId=a0451989628be, content=<a href='/topic/show?id=30f755204c' target=_blank style='color:#2F92EE;'>#CVID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5520, encryptionId=30f755204c, topicName=CVID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 30 03:20:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724406, encodeId=d0021e2440615, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Nov 23 02:20:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952643, encodeId=d24319526438d, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Sep 13 03:20:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981955, encodeId=5b8419819559a, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 23 11:20:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411700, encodeId=1cbe1411e007a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619344, encodeId=2e1a161934434, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=)]
    2012-10-30 w363522449

    #CVID#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1989628, encodeId=a0451989628be, content=<a href='/topic/show?id=30f755204c' target=_blank style='color:#2F92EE;'>#CVID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5520, encryptionId=30f755204c, topicName=CVID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 30 03:20:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724406, encodeId=d0021e2440615, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Nov 23 02:20:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952643, encodeId=d24319526438d, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Sep 13 03:20:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981955, encodeId=5b8419819559a, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 23 11:20:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411700, encodeId=1cbe1411e007a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619344, encodeId=2e1a161934434, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=)]
    2012-11-23 feifers

    #继发#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1989628, encodeId=a0451989628be, content=<a href='/topic/show?id=30f755204c' target=_blank style='color:#2F92EE;'>#CVID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5520, encryptionId=30f755204c, topicName=CVID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 30 03:20:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724406, encodeId=d0021e2440615, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Nov 23 02:20:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952643, encodeId=d24319526438d, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Sep 13 03:20:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981955, encodeId=5b8419819559a, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 23 11:20:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411700, encodeId=1cbe1411e007a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619344, encodeId=2e1a161934434, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=)]
    2012-09-13 xzw113

    #继发性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1989628, encodeId=a0451989628be, content=<a href='/topic/show?id=30f755204c' target=_blank style='color:#2F92EE;'>#CVID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5520, encryptionId=30f755204c, topicName=CVID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 30 03:20:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724406, encodeId=d0021e2440615, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Nov 23 02:20:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952643, encodeId=d24319526438d, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Sep 13 03:20:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981955, encodeId=5b8419819559a, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 23 11:20:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411700, encodeId=1cbe1411e007a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619344, encodeId=2e1a161934434, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=)]
    2013-07-23 caobinglei8079

    #JCI#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1989628, encodeId=a0451989628be, content=<a href='/topic/show?id=30f755204c' target=_blank style='color:#2F92EE;'>#CVID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5520, encryptionId=30f755204c, topicName=CVID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 30 03:20:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724406, encodeId=d0021e2440615, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Nov 23 02:20:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952643, encodeId=d24319526438d, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Sep 13 03:20:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981955, encodeId=5b8419819559a, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 23 11:20:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411700, encodeId=1cbe1411e007a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619344, encodeId=2e1a161934434, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=)]
    2012-09-09 oliver170

    #联合化疗#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1989628, encodeId=a0451989628be, content=<a href='/topic/show?id=30f755204c' target=_blank style='color:#2F92EE;'>#CVID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5520, encryptionId=30f755204c, topicName=CVID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Tue Oct 30 03:20:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724406, encodeId=d0021e2440615, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Fri Nov 23 02:20:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1952643, encodeId=d24319526438d, content=<a href='/topic/show?id=a37ce8961a1' target=_blank style='color:#2F92EE;'>#继发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78961, encryptionId=a37ce8961a1, topicName=继发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Thu Sep 13 03:20:00 CST 2012, time=2012-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981955, encodeId=5b8419819559a, content=<a href='/topic/show?id=12c010266f0' target=_blank style='color:#2F92EE;'>#JCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10266, encryptionId=12c010266f0, topicName=JCI)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5e30378, createdName=caobinglei8079, createdTime=Tue Jul 23 11:20:00 CST 2013, time=2013-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411700, encodeId=1cbe1411e007a, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619344, encodeId=2e1a161934434, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Sep 09 02:20:00 CST 2012, time=2012-09-09, status=1, ipAttribution=)]
    2012-09-09 docwu2019

    #有效治疗#

    0

相关资讯

Cell：改动化疗药物顺序 或增强抗癌效果

       来自麻省理工David H. Koch癌症研究所，哈佛大学的研究人员发表了一篇文章，指出换个顺序使用抗癌药物，能重排细胞凋亡信号网络，从而增强细胞死亡。相关成果公布在Cell杂志上，并被作为头条内容推荐。        领导这一研究的是麻省理工David H. Koch 癌症研究所Michael B